Rigel Pharmaceuticals

NASDAQ:RIGL  
2.44
+0.14 (+6.09%)
Regulatory, Other Pre-Announcement

Rigel Pharmaceuticals Sees Q4 Revenue About $20.4 Mln

Published: 01/10/2022 14:04 GMT
Rigel Pharmaceuticals (RIGL) - Sees Q4 Revenue About $20.4 Million.
Tavalisse Preliminary 2021 Net Product Sales of Approximately $63.0 Million.
Topline Data From Phase 3 Clinical Trial in Warm Autoimmune Hemolytic Anemia (waiha) Expected in Mid-2022.
R289 to Start Open-label Phase 2 Study in Low-risk Myeloid Dysplastic Syndrome (mds) in Q1 2022.
R552 Will Advance Into Phase 2 Development in Psoriasis in 1h 2022 With Partner Lilly.
For Q4 of 2021, Rigel Expects to Report Total Revenue of Approximately $20.4 Million.
Q4 Revenue View $23.4 Million -- Refinitiv Ibes Data (analyst estimates).